Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Uppe… (NCT03338114) | Clinical Trial Compass
WithdrawnPhase 1/2
Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS
Stopped: Sponsor Decision
United States0Started 2017-11
Plain-language summary
The FLX-787-106 study will determine how well FLX-787-ODT works to reduce fasciculations in patients with Amyotrophic Lateral Sclerosis (ALS). The study will measure how often fasciculations occur, and monitor any side effects that might develop while taking the investigational product. Participants will be assessed before and after taking a single dose of FLX-787-ODT. Approximately 15 people will take part in this study at one center in the United States. Participants will be in the study for a single clinic visit and receive a telephone call 7 days later to monitor for side effects.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Documented diagnosis of ALS diagnosis of less than 3 years.
* Expected survival \> 6 months
* Frequent fasciculations noted during clinical examination of any single muscle (\>6 visible fasciculations per minute) observed in Part I
* Normal oral cavity exam at screening
* Proficient in English
* Male subjects will either be surgically sterile or agree to use a medically acceptable method of contraception during sexual contact with females of childbearing potential, and will refrain from sperm donation for 45 days following the study
* Male subjects will either be surgically sterile or agree to use a medically acceptable method of contraception during sexual contact with females of childbearing potential, and will refrain from sperm donation for 45 days following the study
Exclusion Criteria:
* Presence of clinically significant or unstable condition that would result in an increased risk of study participation or difficulty in interpretation of the study results
* Tremor or other movement disorder that would interfere with recording
* Inability to lie flat
* Presence of major gastrointestinal disorders, such as inflammatory bowel disease, diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or esophageal lesions/ulcers
* Presence of laryngospasm or significant swallowing problems
* Presence of percutaneous endoscopic gastrostomy, esophagog…
What they're measuring
1
Change from Baseline of Diastolic Blood Pressure in mmHg
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
2
Change from Baseline of Systolic Blood Pressure in mmHg
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
3
Change from Baseline in Heart Rate in beats per minute
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
4
Change from Baseline in Respiration Rate in breaths per minute
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
5
Change from Baseline in Body Temperature in degrees Celsius or Fahrenheit
Timeframe: Prior to and within 3 hours following administration of investigational product on the single clinic visit
6
Change from Baseline of Oral Cavity Examination
Timeframe: Prior to and twice within 4 hours following administration of investigational product on the clinic visit
Timeframe: Prior to and following administration of investigational product on the clinic visit with AEs followed for 7 days after by telephone contact